Stifel Financial Corp Grows Stake in Elanco Animal Health Incorporated (NYSE:ELAN)

Stifel Financial Corp increased its holdings in Elanco Animal Health Incorporated (NYSE:ELAN) by 82.4% during the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 112,102 shares of the company’s stock after buying an additional 50,637 shares during the period. Stifel Financial Corp’s holdings in Elanco Animal Health were worth $1,647,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in ELAN. Atom Investors LP raised its holdings in shares of Elanco Animal Health by 310.3% in the 3rd quarter. Atom Investors LP now owns 345,855 shares of the company’s stock valued at $5,081,000 after acquiring an additional 261,559 shares in the last quarter. Davidson Kempner Capital Management LP purchased a new stake in Elanco Animal Health in the second quarter valued at approximately $839,000. Edgestream Partners L.P. bought a new stake in Elanco Animal Health during the third quarter valued at approximately $925,000. XTX Topco Ltd bought a new stake in Elanco Animal Health during the second quarter valued at approximately $935,000. Finally, Canada Pension Plan Investment Board purchased a new position in Elanco Animal Health in the 2nd quarter worth approximately $55,599,000. Institutional investors own 97.48% of the company’s stock.

Elanco Animal Health Price Performance

Shares of Elanco Animal Health stock opened at $11.63 on Friday. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.55 and a quick ratio of 1.31. Elanco Animal Health Incorporated has a one year low of $11.40 and a one year high of $18.80. The business’s 50 day simple moving average is $13.02 and its two-hundred day simple moving average is $14.19. The stock has a market capitalization of $5.75 billion, a P/E ratio of 29.08, a price-to-earnings-growth ratio of 2.03 and a beta of 1.41.

Elanco Animal Health (NYSE:ELAN) last issued its earnings results on Thursday, November 7th. The company reported $0.13 EPS for the quarter, topping the consensus estimate of $0.12 by $0.01. The company had revenue of $1.03 billion for the quarter, compared to the consensus estimate of $1.04 billion. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The firm’s revenue for the quarter was down 3.6% on a year-over-year basis. During the same period in the previous year, the firm earned $0.18 earnings per share. Analysts forecast that Elanco Animal Health Incorporated will post 0.92 EPS for the current year.

Analyst Ratings Changes

A number of analysts have recently issued reports on ELAN shares. UBS Group assumed coverage on shares of Elanco Animal Health in a report on Monday, December 9th. They set a “buy” rating and a $18.00 price objective for the company. Stifel Nicolaus reaffirmed a “buy” rating and set a $20.00 price target on shares of Elanco Animal Health in a research note on Thursday, September 19th. Leerink Partnrs upgraded Elanco Animal Health to a “hold” rating in a research report on Monday, December 2nd. Leerink Partners started coverage on Elanco Animal Health in a research report on Monday, December 2nd. They issued a “market perform” rating and a $14.00 target price for the company. Finally, Barclays increased their price target on shares of Elanco Animal Health from $19.00 to $20.00 and gave the company an “overweight” rating in a research report on Friday, November 8th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $16.71.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.